LIVIVO - The Search Portal for Life Sciences

zur deutschen Oberfläche wechseln
Advanced search

Search results

Result 1 - 10 of total 20

Search options

  1. Article ; Online: Comment on a recent article titled 'Hepatocyte nuclear factor 1B deletion, but not intragenic mutation, might be more susceptible to hypomagnesemia'.

    Clissold, Rhian / Bingham, Coralie / Hattersley, Andrew

    Journal of diabetes investigation

    2023  

    Language English
    Publishing date 2023-12-23
    Publishing country Japan
    Document type Letter
    ZDB-ID 2625840-7
    ISSN 2040-1124 ; 2040-1116
    ISSN (online) 2040-1124
    ISSN 2040-1116
    DOI 10.1111/jdi.14137
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  2. Article ; Online: A case of acute tubulointerstitial nephritis following administration of the Oxford-AstraZeneca COVID-19 vaccine: a case report.

    Williams, Samuel B M / Holwill, Stephen D J / Clissold, Rhian L / Bingham, Coralie

    BMC nephrology

    2023  Volume 24, Issue 1, Page(s) 52

    Abstract: Background: More than 4 billion doses of the Coronavirus disease (COVID-19) vaccine have been administered worldwide but the relationship between the different vaccines and the development of renal disease is unknown. We present a case of ... ...

    Abstract Background: More than 4 billion doses of the Coronavirus disease (COVID-19) vaccine have been administered worldwide but the relationship between the different vaccines and the development of renal disease is unknown. We present a case of tubulointerstitial nephritis following administration of the Oxford-AstraZeneca COVID-19 vaccine.
    Case presentation: A previously fit and well 51-year-old female presented on 27th May 2021 with a one-month history of weight loss, fatigue, nausea, and a metallic taste. She had an acute kidney injury with a creatinine of 484 umol/L. She was on no regular medications and denied taking any over-the-counter or alternative medicines. She had received her first dose of the Oxford-AstraZeneca vaccine on 23rd March 2021 and her second dose on 20th May 2021. A renal biopsy was performed the following day. The 19 glomeruli appeared normal to light microscopy but the tubulointerstitial compartment contained a dense inflammatory infiltrate including many eosinophils. There was widespread acute tubular injury with tubulitis, but no established or longstanding atrophy. A diagnosis was made of an acute tubulointerstitial nephritis. She was commenced on oral prednisolone and her renal function improved. She did not require renal replacement therapy at any time.
    Conclusions: To our knowledge, this was the first described case of acute tubulointerstitial nephritis following administration of the Oxford-AstraZeneca COVID-19 vaccine, although a number of cases have emerged more recently. In our case the patient was very fit and well, had no previous past medical history and had not taken any recent prescribed, over-the-counter or alternative medications. The absence of these provoking factors in our case makes the vaccine the most likely explanation for the development of tubulointerstitial nephritis although the pathophysiology behind this remains unknown. Given the unprecedented number of vaccinations being delivered around the world, nephrologists should be aware of this possible link although more research into the topic is required.
    MeSH term(s) Humans ; Female ; Middle Aged ; COVID-19 Vaccines/adverse effects ; ChAdOx1 nCoV-19 ; COVID-19 ; Nephritis, Interstitial/chemically induced ; Nephritis, Interstitial/diagnosis ; Vaccination
    Chemical Substances COVID-19 Vaccines ; ChAdOx1 nCoV-19 (B5S3K2V0G8)
    Language English
    Publishing date 2023-03-14
    Publishing country England
    Document type Case Reports ; Journal Article
    ZDB-ID 2041348-8
    ISSN 1471-2369 ; 1471-2369
    ISSN (online) 1471-2369
    ISSN 1471-2369
    DOI 10.1186/s12882-023-03089-2
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  3. Article: Familial interstitial nephritis: 42 years from case series to genetic diagnosis.

    Clissold, Rhian L / Bingham, Coralie / Shaw-Smith, Charles

    Clinical nephrology

    2019  Volume 91, Issue 6, Page(s) 386–388

    Language English
    Publishing date 2019-01-28
    Publishing country Germany
    Document type Letter
    ZDB-ID 185101-9
    ISSN 0301-0430
    ISSN 0301-0430
    DOI 10.5414/CN109654
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  4. Article ; Online: Recurrent 17q12 microduplications contribute to renal disease but not diabetes.

    Cannon, Stuart / Clissold, Rhian / Sukcharoen, Kittiya / Tuke, Marcus / Hawkes, Gareth / Beaumont, Robin N / Wood, Andrew R / Gilchrist, Mark / Hattersley, Andrew T / Oram, Richard A / Patel, Kashyap / Wright, Caroline / Weedon, Michael N

    Journal of medical genetics

    2022  Volume 60, Issue 5, Page(s) 491–497

    Abstract: Background: 17q12 microdeletion and microduplication syndromes present as overlapping, multisystem disorders. We assessed the disease phenotypes of individuals with 17q12 CNV in a population-based cohort.: Methods: We investigated 17q12 CNV using ... ...

    Abstract Background: 17q12 microdeletion and microduplication syndromes present as overlapping, multisystem disorders. We assessed the disease phenotypes of individuals with 17q12 CNV in a population-based cohort.
    Methods: We investigated 17q12 CNV using microarray data from 450 993 individuals in the UK Biobank and calculated disease status associations for diabetes, liver and renal function, neurological and psychiatric traits.
    Results: We identified 11 17q12 microdeletions and 106 microduplications. Microdeletions were strongly associated with diabetes (p=2×10
    Conclusion: We demonstrate 17q12 microdeletions but not microduplications are associated with diabetes in a population-based cohort, likely caused by
    MeSH term(s) Humans ; Chromosome Deletion ; Kidney Diseases/genetics ; Diabetes Mellitus/genetics ; Kidney ; Phenotype
    Language English
    Publishing date 2022-09-15
    Publishing country England
    Document type Journal Article ; Research Support, Non-U.S. Gov't
    ZDB-ID 220881-7
    ISSN 1468-6244 ; 0022-2593
    ISSN (online) 1468-6244
    ISSN 0022-2593
    DOI 10.1136/jmg-2022-108615
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  5. Article ; Online: Comment on Dubois-Laforgue et al. Diabetes, Associated Clinical Spectrum, Long-term Prognosis, and Genotype/Phenotype Correlations in 201 Adult Patients With Hepatocyte Nuclear Factor 1B (

    Clissold, Rhian L / Harries, Lorna W / Ellard, Sian / Bingham, Coralie / Hattersley, Andrew T

    Diabetes care

    2017  Volume 41, Issue 1, Page(s) e7

    MeSH term(s) Adult ; Diabetes Mellitus, Type 2 ; Genetic Association Studies ; Genotype ; Hepatocyte Nuclear Factor 1-beta/genetics ; Humans ; Mutation ; Phenotype ; Prognosis
    Chemical Substances HNF1B protein, human ; Hepatocyte Nuclear Factor 1-beta (138674-15-4)
    Language English
    Publishing date 2017-12-20
    Publishing country United States
    Document type Letter ; Research Support, Non-U.S. Gov't ; Comment
    ZDB-ID 441231-x
    ISSN 1935-5548 ; 0149-5992
    ISSN (online) 1935-5548
    ISSN 0149-5992
    DOI 10.2337/dc17-1672
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  6. Article: Late presentation of toxoplasmosis in renal transplant recipients.

    Clissold, Rhian / Bingham, Coralie

    NDT plus

    2010  Volume 3, Issue 5, Page(s) 480–482

    Abstract: Toxoplasma gondii is a rare cause of infection in renal transplant recipients and usually occurs within 3 months of transplantation, this being the period of maximum immunosuppression. We report two cases of toxoplasmosis presenting several years after ... ...

    Abstract Toxoplasma gondii is a rare cause of infection in renal transplant recipients and usually occurs within 3 months of transplantation, this being the period of maximum immunosuppression. We report two cases of toxoplasmosis presenting several years after transplantation. One patient developed Toxoplasma retinitis 4 years after renal transplantation and lost peripheral vision in his affected eye. Another developed cerebral toxoplasmosis 6 years following his second renal transplant but did not survive despite treatment. These cases highlight the need for a high index of suspicion of toxoplasmosis as a potential diagnosis even during the later stages of the post-transplant period as survival is poor without early recognition and treatment.
    Language English
    Publishing date 2010-06-17
    Publishing country England
    Document type Journal Article
    ZDB-ID 2410383-4
    ISSN 1753-0784
    ISSN 1753-0784
    DOI 10.1093/ndtplus/sfq113
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  7. Article: Insulin glargine in the management of diabetes mellitus: an evidence-based assessment of its clinical efficacy and economic value.

    Clissold, Rhian / Clissold, Steve

    Core evidence

    2007  Volume 2, Issue 2, Page(s) 89–110

    Abstract: Introduction: Diabetes is a chronic disease associated with high morbidity and mortality, which represents a major public health concern. Interventions that can enhance patient care and reduce clinic visits will not only relieve some of this burden, ... ...

    Abstract Introduction: Diabetes is a chronic disease associated with high morbidity and mortality, which represents a major public health concern. Interventions that can enhance patient care and reduce clinic visits will not only relieve some of this burden, they will also improve patient QOL and wellbeing.
    Aims: This review assesses the evidence for the use of insulin glargine in type 1 and type 2 diabetes mellitus.
    Evidence review: Once-daily insulin glargine has a prolonged, peakless activity profile, making it a candidate as a long-acting (basal) insulin. In combination with bolus insulin to cover prandial glucose surges, it facilitates a more physiologic approach to patient management. Evidence from large, randomized, controlled clinical trials in patients with type 1 diabetes has confirmed its effectiveness and tolerability relative to neutral protamine hagedorn (NPH) insulin, with a tendency toward causing less hypoglycemia. In patients with type 2 diabetes requiring insulin therapy, once-daily insulin glargine has proven to be clinically superior to NPH insulin in terms of providing at least as effective glycemic control, but with significantly fewer episodes of nocturnal hypoglycemia. A variety of economic analyses have confirmed the cost effectiveness of insulin glargine in type 1 and type 2 diabetes and in particular it was shown to be significantly superior to NPH insulin.
    Clinical value: Insulin glargine has established itself as a first-line choice in patients with type 1 diabetes, including children (>6 years) and adolescents, and is a recommended treatment option. In patients with type 2 diabetes it is clearly associated with less hypoglycemia than NPH insulin, and this may help overcome one of the major barriers to starting insulin therapy in this class of patient. Thus, insulin glargine is a valuable addition to the therapeutic armamentarium available to physicians and it has the potential to significantly improve the quality of life of patients with diabetes.
    Language English
    Publishing date 2007-11-30
    Publishing country New Zealand
    Document type Journal Article
    ZDB-ID 2520695-3
    ISSN 1555-175X ; 1555-1741
    ISSN (online) 1555-175X
    ISSN 1555-1741
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  8. Article ; Online: Assessment of the HNF1B Score as a Tool to Select Patients for HNF1B Genetic Testing.

    Clissold, Rhian / Shields, Beverley / Ellard, Sian / Hattersley, Andrew / Bingham, Coralie

    Nephron

    2015  Volume 130, Issue 2, Page(s) 134–140

    Abstract: Background/aims: Diagnosing hepatocyte nuclear factor 1β (HNF1B)-related disease is a challenging task due to the phenotypic variability and frequent absence of a family history. An HNF1B score has recently been developed to help select appropriate ... ...

    Abstract Background/aims: Diagnosing hepatocyte nuclear factor 1β (HNF1B)-related disease is a challenging task due to the phenotypic variability and frequent absence of a family history. An HNF1B score has recently been developed to help select appropriate patients for genetic testing with a negative predictive value (NPV) of 99%. We aimed at testing the clinical utility of this score in a large number of referrals for HNF1B genetic testing to the UK diagnostic testing service for the HNF1B gene.
    Methods: An HNF1B score was assigned for 686 UK referrals for HNF1B genetic testing using clinical information available at referral. The performance of the score was evaluated by receiver-operating characteristic curve analysis. The relative discriminatory ability of different clinical features for making a genetic diagnosis of HNF1B-related disease were estimated in the UK dataset alone and pooled with French data.
    Results: The HNF1B score discriminated between patients with and without a mutation reasonably well with an area under the curve of 0.72. Applying the suggested cut-off score of ≥8 gave a NPV of 85%. In a pooled analysis, antenatal renal abnormalities, renal hyperechogenicity and cysts were discriminatory in children, whereas renal hypoplasia and cysts were discriminatory in adults. Pancreatic abnormalities were discriminatory in both, whereas other extra-renal characteristics had a large effect size only in adults.
    Conclusion: The HNF1B score was discriminatory for HNF1B mutations in a large cohort of individuals tested in a single UK centre. The lower NPV (85 vs. 99%) reduces its clinical utility in selecting patients for HNF1B genetic testing, although validation in a prospective cohort is required.
    MeSH term(s) Cohort Studies ; Genetic Testing ; Hepatocyte Nuclear Factor 1-beta/genetics ; Heterozygote ; Humans ; Mutation
    Chemical Substances HNF1B protein, human ; Hepatocyte Nuclear Factor 1-beta (138674-15-4)
    Language English
    Publishing date 2015-05-22
    Publishing country Switzerland
    Document type Journal Article ; Research Support, Non-U.S. Gov't
    ZDB-ID 207121-6
    ISSN 2235-3186 ; 1423-0186 ; 1660-8151 ; 0028-2766
    ISSN (online) 2235-3186 ; 1423-0186
    ISSN 1660-8151 ; 0028-2766
    DOI 10.1159/000398819
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  9. Article ; Online: Sociodemographic, Psychologic Health, and Lifestyle Outcomes in Young Adults on Renal Replacement Therapy.

    Hamilton, Alexander J / Clissold, Rhian L / Inward, Carol D / Caskey, Fergus J / Ben-Shlomo, Yoav

    Clinical journal of the American Society of Nephrology : CJASN

    2017  Volume 12, Issue 12, Page(s) 1951–1961

    Abstract: Background and objectives: Young adults receiving RRT face additional challenges in life. The effect of established kidney failure on young adulthood is uncertain. We aimed to establish the psychosocial and lifestyle status of young adults receiving RRT. ...

    Abstract Background and objectives: Young adults receiving RRT face additional challenges in life. The effect of established kidney failure on young adulthood is uncertain. We aimed to establish the psychosocial and lifestyle status of young adults receiving RRT.
    Design, setting, participants, & measurements: Our study was a systematic review and meta-analysis of 16-30-year olds receiving RRT compared with the general population. We selected randomized, controlled trials; cohort studies; or cross-sectional studies without language restriction and extracted proportions of sociodemographic and lifestyle outcomes or validated psychologic health tests producing quality of life, wellbeing, and self-esteem scores. We undertook random effects meta-analysis.
    Results: There were 60 studies with a total of 15,575 participants. Studies were largely single-center cross-sectional studies of those transplanted in childhood. Compared with healthy peers, young adults on RRT had lower quality of life, which was worse for patients on dialysis (seven studies: standardized mean difference, -1.01; 95% confidence interval [95% CI], -1.32 to -0.70) compared with patients with transplants (nine studies: standardized mean difference, -0.42; 95% CI, -0.64 to -0.20). They were more likely to be unemployed (seven studies: relative risk, 1.89; 95% CI, 1.47 to 2.44) and live in the family home (two studies: relative risk, 1.84; 95% CI, 1.40 to 2.43). They were less likely to be married or have a partner (four studies: relative risk, 0.71; 95% CI, 0.53 to 0.95). Higher education (three studies: relative risk, 1.05; 95% CI, 0.73 to 1.51), alcohol abstinence (three studies: relative risk, 1.96; 95% CI, 0.84 to 4.67), and smoking status (two studies: relative risk, 0.72; 95% CI, 0.36 to 1.44) did not differ. Results were limited by high heterogeneity and a small evidence base, biased toward surviving patients.
    Conclusions: Established kidney failure is associated with lower quality of life in young people and limited employment, independence, and relationships compared with healthy peers.
    Podcast: This article contains a podcast at https://www.asn-online.org/media/podcast/CJASN/2017_10_19_CJASNPodcast_17_12_.mp3.
    MeSH term(s) Humans ; Life Style ; Marital Status ; Mental Health ; Quality of Life ; Renal Insufficiency, Chronic/psychology ; Renal Insufficiency, Chronic/therapy ; Renal Replacement Therapy/psychology ; Unemployment ; Young Adult
    Language English
    Publishing date 2017-10-19
    Publishing country United States
    Document type Journal Article ; Meta-Analysis ; Review ; Systematic Review
    ZDB-ID 2226665-3
    ISSN 1555-905X ; 1555-9041
    ISSN (online) 1555-905X
    ISSN 1555-9041
    DOI 10.2215/CJN.04760517
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  10. Article ; Online: Insulin glargine in the management of diabetes mellitus

    Rhian Clissold / Steve Clissold

    Core Evidence, Vol 2007, Iss Issue

    an evidence-based assessment of its clinical efficacy and economic value

    2007  Volume 2

    Abstract: Rhian Clissold1, Steve Clissold21Endocrinology Department, Frenchay Hospital, Bristol, UK; 2Content ...

    Abstract Rhian Clissold1, Steve Clissold21Endocrinology Department, Frenchay Hospital, Bristol, UK; 2Content Ed Net Communications S.L., Madrid, SpainIntroduction: Diabetes is a chronic disease associated with high morbidity and mortality, which represents a major public health concern. Interventions that can enhance patient care and reduce clinic visits will not only relieve some of this burden, they will also improve patient QOL and wellbeing.Aims: This review assesses the evidence for the use of insulin glargine in type 1 and type 2 diabetes mellitus.Evidence review: Once-daily insulin glargine has a prolonged, peakless activity profile, making it a candidate as a long-acting (basal) insulin. In combination with bolus insulin to cover prandial glucose surges, it facilitates a more physiologic approach to patient management. Evidence from large, randomized, controlled clinical trials in patients with type 1 diabetes has confirmed its effectiveness and tolerability relative to neutral protamine hagedorn (NPH) insulin, with a tendency toward causing less hypoglycemia. In patients with type 2 diabetes requiring insulin therapy, once-daily insulin glargine has proven to be clinically superior to NPH insulin in terms of providing at least as effective glycemic control, but with significantly fewer episodes of nocturnal hypoglycemia. A variety of economic analyses have confirmed the cost effectiveness of insulin glargine in type 1 and type 2 diabetes and in particular it was shown to be significantly superior to NPH insulin.Clinical value: Insulin glargine has established itself as a first-line choice in patients with type 1 diabetes, including children (>6 years) and adolescents, and is a recommended treatment option. In patients with type 2 diabetes it is clearly associated with less hypoglycemia than NPH insulin, and this may help overcome one of the major barriers to starting insulin therapy in this class of patient. Thus, insulin glargine is a valuable addition to the therapeutic armamentarium available to physicians and it has the potential to significantly improve the quality of life of patients with diabetes.Key words: evidence-based review, glycemic control, insulin glargine, insulin therapy, type 1 diabetes, type 2 diabetes
    Keywords Medicine (General) ; R5-920 ; Medicine ; R ; DOAJ:Medicine (General) ; DOAJ:Health Sciences ; Therapeutics. Pharmacology ; RM1-950 ; DOAJ:Therapeutics
    Subject code 571
    Language English
    Publishing date 2007-11-01T00:00:00Z
    Publisher Dove Medical Press
    Document type Article ; Online
    Database BASE - Bielefeld Academic Search Engine (life sciences selection)

    More links

    Kategorien

To top